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Background. We assessed the incidence of tuberculosis, risk factors for tuberculosis, and the contribution of tuberculosis on 
mortality in a large cohort of human immunodeficiency virus (HIV)-infected children <15 years of age initiating first-line antiretro-
viral therapy (ART) between 1999 and 2012 in Thailand, one of the 22 high tuberculosis burden countries.
Methods. A physician reviewed and classified tuberculosis cases. Incidence was the number of children with incident tuber-
culosis, defined as a first or recurrent tuberculosis diagnosis >30 days after ART initiation, divided by the total person-years of fol-
low-up (PYFU). Risk factors for incident tuberculosis were identified using Fine and Gray’s competing risks models, with death from 
other causes treated as a competing event, and risk factors for death were identified using Cox models.
Results. At ART initiation, 670 children (55% female) had a median age of 6.4 years (interquartile range, 2.0–9.6), body mass 
index-for-age z-score −0.8 (−1.9 to 0.0), HIV ribonucleic acid viral load 5.1 log10 copies/mL (4.6–5.6), and CD4 9% (3–17). Median 
duration of follow-up was 7.7 years. Tuberculosis incidence was 7 per 1000 PYFU (95% confidence interval [CI], 5–11) and decreased 
with ART duration. Lower age-adjusted hemoglobin, hematocrit, and CD4 at ART initiation were associated with a higher risk of 
incident tuberculosis. Of the 30 incident tuberculosis cases, 9 died. Diagnosis of incident tuberculosis was associated with mortality 
(unadjusted hazard ratio = 10.2, 95% CI = 4.8–21.5, P < .001 and adjusted hazard ratio = 5.4, 95% CI = 2.5–11.7, P < .001).
Conclusions. Incident tuberculosis was strongly associated with mortality. CD4 counts or hemoglobin or hematocrit levels may 
prompt clinicians to consider a possible tuberculosis infection.
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 In 2014, 9.6 million people developed active tuberculosis world-
wide, including an estimated 1.2 million living with human immu-
nodeficiency virus (HIV) [1]. Tuberculosis remains the primary 
cause of death among HIV-infected people (390 000 deaths) [1, 2]. 
Thailand is one of the 22 high tuberculosis burden countries listed 
by the World Health Organization (WHO), with an incidence of 
171 per 100 000 in the general population in 2014, whereas the 
incidence reported in the HIV-infected population is more than 20 
times higher [1, 3]. Approximately half of the 12 000 people who 
died of tuberculosis in Thailand in 2014 were infected with HIV [1].
In Thailand, data on tuberculosis incidence and associated 
mortality are limited, particularly in children living with HIV 
[4–6], and the long-term risk of tuberculosis in children on 
antiretroviral therapy (ART) is unknown. Within a large mul-
ticenter cohort of HIV-infected children on ART in Thailand, 
we estimated tuberculosis incidence, the impact of different risk 
factors on incident tuberculosis, and the contribution of tuber-
culosis on the risk of death.
METHODS
Study Population
This analysis included all HIV-infected children less than 
15  years of age who initiated first-line ART between January 
1, 1999 and December 31, 2012 and were followed in the 
Program for HIV Prevention and Treatment (PHPT) cohort 
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(ClinicalTrials.gov: NCT00433030) in a network of public hos-
pitals throughout the country, as previously described [7].
Baseline Data and Follow-Up
Children were followed-up at 2 weeks, 1 month, and 3 months 
after initiating ART and every 3 months thereafter for physical 
examination, complete blood count (hemoglobin, hematocrit, 
white blood count, red blood count, platelets, lymphocytes, neu-
trophils), clinical chemistries (plasma glucose, alanine transam-
inase, creatinine), drug refills, and adherence counseling. CD4 
percentage and HIV ribonucleic acid (RNA) viral load were mea-
sured 3 and 6 months after ART initiation and every 6 months 
thereafter. The cohort study protocol included screening for 
tuberculosis before initiating ART and during follow-up in case 
of presumptive symptoms, based on interview, medical history, 
clinical examination, chest x-ray, tuberculin skin test, sputum 
acid-fast bacillus smear and/or gastric aspirate if indicated.
Children who never came back for follow-up during the study 
period were considered lost to follow-up. In the event of a par-
ticipant’s death, the immediate cause and underlying conditions 
were reported by the attending physicians. All death reports were 
reviewed, and causes of death were classified by 2 independent 
physicians based on the International Classification of Diseases [8].
Tuberculosis Case Definition
A physician (C. D.) reviewed all available records of cases with 
suspected tuberculosis infection and classified each tubercu-
losis case as clinically diagnosed with or without bacteriologic 
confirmation, following the WHO reporting guidelines [9].
Children were classified in 4 groups according to their tuber-
culosis infection status: “prevalent tuberculosis” for children with 
ongoing tuberculosis treatment at the time of ART initiation or 
starting within the following 30 days; “incident tuberculosis” for 
children with a first or recurrent tuberculosis diagnosis at least 
30 days after ART initiation; “history of treated tuberculosis” for 
children who had recovered from tuberculosis before ART initia-
tion; and “no tuberculosis” for children who were not diagnosed 
with tuberculosis before ART initiation or during follow-up. The 
choice of the cutoff (30 days) to define “prevalent” and “incident” 
tuberculosis was driven by the literature [10, 11], although it is 
likely that not all tuberculosis infections already established at 
time of ART initiation were diagnosed within 30 days.
Statistical Analysis
The follow-up period was from the date of ART initiation to 
the date of death, date of last clinic visit, or December 31, 2013, 
whichever occurred first. Children with a history of treated 
tuberculosis at time of ART initiation were included in the inci-
dence and risk factor analyses, but those with prevalent tuber-
culosis were excluded.
The incidence of tuberculosis infections diagnosed during fol-
low-up was calculated using person-time incidence rates. Overall 
and stratified incidence rates were defined as the number of inci-
dent tuberculosis cases divided by the number of person-years 
of follow-up (PYFU). The 95% confidence intervals (CIs) of the 
incidence rates were calculated based on the Poisson distribution.
Risk factors for incident tuberculosis were identified using 
univariable and multivariable Fine and Gray’s competing risks 
proportional subhazards models [12], with death from other 
causes treated as a competing event. The association between 
diagnosis of incident tuberculosis and mortality was evaluated 
using univariable and multivariable Cox proportional hazards 
regression models, tuberculosis diagnosis being dichotomized 
and treated as a time-dependent variable (never or ever been 
diagnosed with tuberculosis).
Potential risk factors for incident tuberculosis and mortality 
assessed at ART initiation were as follows: sex, age, body mass 
index (BMI)-for-age [13, 14], calendar year of enrollment, and 
age-adjusted HIV RNA viral load, CD4 percentage, hemoglo-
bin, hematocrit, neutrophils, and lymphocytes. Missing values 
at ART initiation were imputed using multiple imputation by 
chained equations with predictive mean matching (10 impu-
tations) [15]. Except for BMI-for-age and calendar year of 
enrollment, all continuous variables were first categorized into 
quartiles rounded to the nearest clinically meaningful values and 
then put into smaller groups determined by the magnitude of 
the model coefficients in the univariable analyses. Multivariable 
models included all variables with P < .25 in the univariable 
analyses, and a forward selection procedure was used to identify 
risk factors independently associated with incident tuberculosis 
and mortality. The proportional hazards assumption of the mod-
els was tested using an interaction term between independent 
variables and time. Data were censored at the date of last clinic 
visit or December 31, 2013, whichever occurred first.
All reported P values are 2-sided, and P < .05 was considered 
statistically significant. Missing data imputation and statistical 
analyses were performed using Stata 13.0 (StataCorp, College 
Station, TX).
Ethical Considerations
The PHPT Cohort protocol and subsequent amendments were 
approved by the Ethics Committees of the Thai Ministry of 
Public Health, the Faculty of Associated Medical Sciences at 
Chiang Mai University, and local hospital ethics committees.
RESULTS
Study Population Characteristics
A total of 670 children were eligible for inclusion (Figure  1), 
including 367 (55%) females. At ART initiation, median age 
was 6.4  years (interquartile range [IQR], 2.0 to 9.6), BMI-
for-age z-score was −0.8 (IQR, −1.9 to 0.0), HIV RNA viral 
load was 5.1 log10 copies/mL (IQR, 4.6 to 5.6), and CD4 was 
9% (IQR, 3 to 17)  (Table 1). Fifty-five children (8%) received 
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isoniazid preventive therapy at some point during the study period. 
The median duration of follow-up from ART initiation was 
7.7 years (IQR, 3.6 to 9.8). Of the 670 children, 14 had a his-
tory of treated tuberculosis. At the end of the study, 377 (56%) 
children were no longer on follow-up: 161 voluntarily withdrew 
from the study, 160 were lost to follow-up, and 56 died.
Description of Tuberculosis Cases
Of the 670 children, 77 (11%) experienced tuberculosis. Of these 
77 cases, 47 were prevalent (none of them experienced recur-
rent tuberculosis after ART initiation) and 30 incident (includ-
ing 2 with a history of treated tuberculosis before ART initiation 
and 1 with 2 tuberculosis episodes after ART initiation). Eight 
were bacteriologically confirmed and 69 were clinically diag-
nosed. There were 56 pulmonary, 12 lymphadenitis, 2 menin-
gitis, 2 abdominal, 1 pulmonary plus meningitis, 1 parotid and 
1 cutaneous tuberculosis, and 2 unspecified tuberculosis sites.
During tuberculosis treatment, 54 received an efa-
virenz-based ART regimen, 8 received a nevirapine-based 
regimen, 7 received a protease inhibitor-based regimen, and 4 
received a zidovudine plus didanosine regimen; 3 discontinued 
ART before tuberculosis treatment; and 1 died before starting 
tuberculosis treatment. Based on the data available, which were 
mostly collected before consensus definitions of immune recon-
stitution inflammatory syndrome (IRIS) were proposed [16], 
the physician in charge of the retrospective review suspected 
that 8 children (3 with a prevalent tuberculosis and 5 with an 
incident tuberculosis) developed an IRIS between 10 days and 
4 months after ART initiation. However, the information avail-
able was not sufficient to definitely classify these cases.
Tuberculosis Incidence
After exclusion of the 47 prevalent tuberculosis cases, 623 chil-
dren contributed to 4068 PYFU. There were 30 incident tuber-
culosis cases, leading to an overall crude tuberculosis incidence 
rate of 7 per 1000 PYFU (95% CI, 5–11) (when including the 
47 prevalent tuberculosis cases in the calculation, the incidence 
was similar: 7 per 1 000 PYFU [95% CI, 5–10]). The incidence 
rate was 4 per 1000 PYFU in males (95% CI, 2–8) and 10 per 
1000 PYFU in females (95% CI, 7–16). Median duration of fol-
low-up between ART initiation and tuberculosis diagnosis was 
15 months (IQR, 3–65). Incidence rates sharply decreased with 
the duration of follow-up, from 60 per 1000 PYFU (95% CI, 
31–115) from 1 to 3 months after ART initiation to 5 per 1000 
PYFU (95% CI, 2–10) after 5 years (Figure 2).
Risk Factors for Incident Tuberculosis
In the univariable analysis to identify risk factors for incident 
tuberculosis, female sex (subhazard ratio [SHR] = 2.7, P = .02) 
and age-adjusted CD4  <5% (SHR  =  3.5, P  =  .01), hemoglo-
bin <9 g/dL (SHR = 2.7, P = .03), hematocrit <30% (SHR 2.5, 
P = .02), and lymphocytes <2000 cells/mm3 (SHR = 3.2, P = .04) 
at ART initiation were associated with a higher risk of incident 
tuberculosis (Table 2). In the multivariable analysis, female sex 
(adjusted SHR [aSHR] = 2.9, 95% CI = 1.3–6.8, P =  .01) and 
age-adjusted CD4  <5% at ART initiation (aSHR  =  3.9, 95% 
CI  =  1.5–10.1, P  =  .006) were independently associated with 
a higher risk of incident tuberculosis. The same factors were 
found associated with incident tuberculosis when the anal-
ysis was restricted to children with complete data (female 
sex: aSHR = 2.8, 95% CI = 1.2–6.6, P =  .02, and age-adjusted 
CD4 <5%: aSHR = 3.8, 95% CI = 1.5–10.0, P = .006).
Mortality
Diagnosis of incident tuberculosis was associated with a higher 
risk of mortality in both the univariable analysis (hazard ratio 
[HR] = 10.2, 95% CI = 4.8–21.5, P < .001) and the multivariable 
analysis adjusting for age, BMI-for-age, CD4 percentage, and 
hemoglobin levels at ART initiation (adjusted HR = 5.4, 95% 
CI = 2.5–11.7, P < .001) (Table 3).
Of the 30 incident tuberculosis cases, 9 (30%) died: 1 on the 
day after tuberculosis diagnosis, 3 while still on tuberculosis 
Figure 1. Study population flowchart. ART, antiretroviral therapy; HIV, human immunodeficiency virus; PHPT, Program for HIV Prevention and Treatment.
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treatment, and 5 after completion of tuberculosis treatment. 
In this group of 9 children, 3 had a tuberculosis bacteriologi-
cally confirmed (2 pulmonary and 1 cutaneous) and 6 clinically 
diagnosed (5 pulmonary and 1 lymphadenitis). Ages at death 
were 1.3, 1.7, 6.5, 10.0, 12.1, 13.9, 14.9, 17.5, and 20.3  years. 
The median survival time after tuberculosis diagnosis was 
5 months, and 2 had a concurrent acquired immune deficiency 
syndrome-defining event (progressive multifocal leukoenceph-
alopathy and cryptococcal meningitis).
DISCUSSION
In this large prospective cohort of 670 HIV-infected chil-
dren initiating ART in Thailand and followed for a median of 
Table 1. Study Population Characteristics at ART Initiation
Characteristics at ART Initiation Prevalent Tuberculosis 
(n = 47a) n (%)
Incident Tuberculosis 
(n = 30a) n (%)
No Tuberculosis 
(n = 593a) n (%)
Overall  
(n = 670a) n (%)
Female sex 26 (55) 23 (77) 318 (54) 367 (55)
 Age
 <2 years 6 (13) 7 (23) 153 (26) 166 (25)
 2 to 6 years 10 (21) 4 (13) 138 (23) 152 (23)
 6 to 10 years 19 (40) 8 (27) 180 (30) 207 (31)
 ≥10 years 12 (26) 11 (37) 122 (21) 145 (22)
BMI-for-age (n = 43) (n = 27) (n = 527) (n = 597)
 z-score < −2 16 (37) 9 (33) 131 (25) 156 (26)
 z-score between −2 and +1 24 (56) 17 (63) 347 (66) 388 (65)
 z-score ≥ +1 3 (7) 1 (4) 49 (9) 53 (9)
Calendar Year of Enrollment
 1999 to 2002 5 (11) 4 (13) 111 (19) 120 (18)
 2003 to 2005 33 (70) 22 (73) 331 (56) 386 (58)
 2006 to 2012 9 (19) 4 (13) 151 (25) 164 (24)
HIV RNA viral load (n = 37) (n = 23) (n = 460) (n = 520)
 <4.5 log10 copies/mL 2 (5) 4 (17) 91 (20) 97 (19)
 4.5 to 5.0 log10 copies/mL 7 (19) 4 (17) 88 (19) 99 (19)
 5.0 to 5.5 log10 copies/mL 13 (35) 5 (22) 131 (28) 149 (29)
 ≥5.5 log10 copies/mL 15 (41) 10 (43) 150 (33) 175 (34)
CD4 (n = 45) (n = 29) (n = 562) (n = 636)
 <5% 19 (42) 18 (62) 192 (34) 229 (36)
 5% to 10% 9 (20) 2 (7) 100 (18) 111 (17)
 10% to 15% 12 (27) 3 (10) 95 (17) 110 (17)
 ≥15% 5 (11) 6 (21) 175 (31) 186 (29)
Hemoglobin (n = 43) (n = 28) (n = 529) (n = 600)
 <9 g/dL 7 (16) 7 (25) 83 (16) 97 (16)
 9 to 10 g/dL 8 (19) 8 (29) 102 (19) 118 (20)
 10 to 11 g/dL 9 (21) 7 (25) 135 (26) 151 (25)
 ≥11 g/dL 19 (44) 6 (21) 209 (40) 234 (39)
Hematocrit (n = 44) (n = 28) (n = 539) (n = 611)
 <30% 9 (20) 12 (43) 146 (27) 167 (27)
 30% to 32% 7 (16) 6 (21) 84 (16) 97 (16)
 32% to 34% 10 (23) 4 (14) 110 (20) 124 (20)
 ≥34% 18 (41) 6 (21) 199 (37) 223 (36)
Neutrophils (n = 43) (n = 28) (n = 509) (n = 580)
 <3000 cells/mm3 28 (65) 7 (25) 222 (44) 257 (44)
 3000 to 4000 cells/mm3 3 (7) 8 (29) 117 (23) 128 (22)
 4000 to 5000 cells/mm3 4 (9) 3 (11) 59 (12) 66 (11)
 ≥5000 cells/mm3 8 (19) 10 (36) 111 (22) 129 (22)
Lymphocytes (n = 43) (n = 28) (n = 509) (n = 580)
 <2000 cells/mm3 22 (51) 18 (64) 191 (38) 231 (40)
 2000 to 3000 cells/mm3 7 (16) 3 (11) 115 (23) 125 (22)
 3000 to 4000 cells/mm3 7 (16) 4 (14) 56 (11) 67 (12)
 ≥4000 cells/mm3 7 (16) 3 (11) 147 (29) 157 (27)
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HIV, human immunodeficiency virus; RNA, ribonucleic acid.
aUnless otherwise specified.
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7.7  years, the overall tuberculosis incidence rate during fol-
low-up was 7 per 1000 PYFU, with a dramatic decrease a few 
months after ART initiation (Figure 2). The estimated incidence 
rate in these HIV-infected children was much higher than in the 
general population of children in Thailand, as previously esti-
mated in 2000 (0.15 per 1000 PYFU) or between 2004 and 2006 
(0.14 per 1000 PYFU) [4, 6].
Despite Thailand being on the list of the 22 high tuberculosis 
burden countries, the incidence rate estimated in this study was 
similar to that reported from studies of HIV-infected children 
in the United States, the United Kingdom and Ireland, and 
China, but it was much lower than in sub-Saharan Africa. The 
tuberculosis incidence rate was 6 per 1000 PYFU in the United 
States (approximately 5-year follow-up) [17], 2 per 1000 PYFU 
in the United Kingdom and Ireland (8 years) [10], and 8 per 
1000 PYFU in China (7 years) [18]. In contrast, the tuberculosis 
incidence rates were 64 per 1000 PYFU in 2 studies in South 
Africa (14 and 10 months, respectively) [19, 20], 175 per 1000 
PYFU in Kenya (8 months) [21], 102 per 1000 PYFU in the 
Democratic Republic of the Congo (23 months) [22], and 52 
Figure 2. Incidence rates of tuberculosis after antiretroviral therapy (ART) initiation, stratified by follow-up duration. Circles: estimated incidence rates per 
stratum of follow-up duration since ART initiation. Segments: 95% confidence intervals of the incidence rates per stratum, calculated based on the Poisson 
distribution. Dotted line: overall incidence rate. 
Table 2. Association Between Characteristics at ART Initiation and Diagnosis of Incident Tuberculosis
Characteristics at ART Initiation Univariable Analysis Multivariable Analysis
SHR (95% CI) P Value aSHR (95% CI) P Value
Female sex 2.7 (1.2 to 6.4) .02 2.9 (1.3 to 6.8) .01
 Age (ref: 2 to 6 years) .16
 <2 years 1.6 (0.5 to 5.5)
 6 to 10 years 1.5 (0.5 to 5.1)
 ≥10 years 3.2 (1.0 to 9.9)
BMI-for-age z-scorea < −2 1.3 (0.6 to 2.9) .49
Calendar year of enrollment (ref: 1999 to 2002) .22
 2003 to 2005 2.3 (0.7 to 7.1)
 2006 to 2012 1.2 (0.3 to 5.1)
HIV RNA viral loada,b ≥5.5 log10 copies/mL 2.5 (0.9 to 7.5) .09
CD4a,b <5% 3.5 (1.3 to 9.2) .01 3.9 (1.5 to 10.1) .006
Hemoglobina,b <9 g/dL 2.7 (1.1 to 6.7) .03
Hematocrita,b <30% 2.5 (1.2 to 5.5) .02
Neutrophilsa,b ≥3000 cells/mm3 2.1 (0.9 to 5.1) .09
Lymphocytesa,b <2000 cells/mm3 3.2 (1.1 to 9.5) .04
Abbreviations: ART, antiretroviral therapy; aSHR, adjusted subhazard ratio; BMI, body mass index; CI, confidence interval; HIV, human immunodeficiency virus; ref, reference; RNA, ribonucleic acid; SHR, subhazard ratio.
aMissing values were imputed using multiple imputation by chained equations with predictive mean matching.
bAdjusted for age.
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per 1000 PYFU in Tanzania (10 months) [23]. This suggests that 
the tuberculosis incidence in HIV-infected children depends on 
the extent of the HIV epidemic in the HIV-infected and unin-
fected adult population; for example, in 2014, the tuberculosis 
incidence in the whole population was 1.8 per 1000 PYFU in 
Thailand compared with 8.3 per 1000 PYFU in South Africa [1].
The sharp decrease in tuberculosis incidence observed a few 
months after ART initiation was similar in previous reports such 
as in Kenya (3550 per 1000 PYFU within the 2  months after 
enrollment, then 460 per 1000 PYFU between 2 and 6 months, 
and 47 per 1000 PYFU after 6 months) [21] and in the Democratic 
Republic of the Congo (from 189 per 1000 PYFU in the first 
6  months to 53 per 1000 PYFU after 12  months) [22]. This is 
likely the result of immune restoration. However, in our study, 
the incidence remained much higher than in the HIV-uninfected 
population: 5 per 1000 PYFU (95% CI, 2–10) after 5 years after 
ART initiation, compared with an estimated 0.15 per 1000 PYFU 
in the general pediatric population in Thailand [4, 6]. This may be 
related to other environmental factors, eg, poverty and social and 
family variables, which are not modified by ART.
As already known in other parts of the world, tuberculosis 
during follow-up was the strongest independent risk factor for 
death, indicating the severity of HIV disease. Simple, inexpen-
sive, and widely available markers, ie, lower hematocrit and 
hemoglobin levels and lower lymphocyte and CD4 counts, are 
indicative of HIV severity and should prompt more investiga-
tions to detect life-threatening complications.
This study has several limitations. First, we used the WHO 
recommendations for diagnosis, ie, tuberculosis was not often 
bacteriologically confirmed. It has to be noted that definitive 
diagnosis of tuberculosis is now somewhat easier, although 
still a challenge, than at the beginning of our study due to 
the increased availability of new diagnostic tools, particularly 
GeneXpert. Second, the results of the analyses assessing risk 
factors need to be interpreted with caution due to the rela-
tively small number of incident tuberculosis cases and deaths 
observed in our cohort. For example, the unexpected associ-
ation of incident tuberculosis with female sex may be due to 
sampling.
CONCLUSIONS
In this large cohort of HIV-infected children in Thailand, 
tuberculosis was mostly diagnosed around the time of ART 
initiation, and the incidence declined soon after but remained 
much higher than the national estimate in the general pediatric 
population. As previously described, incident tuberculosis was 
strongly associated with the risk of death. Our analysis suggests 
that CD4 counts or hemoglobin or hematocrit levels, often rou-
tinely assessed in HIV treatment programs, may prompt clini-
cians to consider a possible tuberculosis infection.
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Table 3. Risk of Death After Diagnosis of Incident Tuberculosis
Characteristics Univariable Analysis Multivariable Analysis
HR (95% CI) P Value aHR (95% CI) P Value
Tuberculosis diagnosis during follow-up (time-dependent variable) 10.2 (4.8 to 21.5) <.001 5.4 (2.5 to 11.7) <.001
Characteristics at ART initiation
Female sex 1.1 (0.6 to 1.9) .71
Age (ref: 2 to 6 years) .08
 <2 years 3.6 (1.3 to 9.8)
 6 to 10 years 2.5 (0.9 to 6.8)
 ≥10 years 3.2 (1.2 to 9.0)
BMI-for-age z-scorea < −2 3.7 (2.1 to 6.5) <.001 2.6 (1.4 to 4.6) .002
Calendar year of enrollment (ref: 1999 to 2002) .35
 2003 to 2005 0.7 (0.3 to 1.2)
 2006 to 2012 0.6 (0.3 to 1.4)
HIV RNA viral loada,b ≥5.5 log10 copies/mL 2.4 (1.2 to 4.7) .01
CD4a,b <5% 3.5 (1.8 to 6.8) <.001 2.2 (1.1 to 4.6) .03
Hemoglobina,b <9 g/dL 3.5 (1.6 to 7.5) .001 2.4 (1.1 to 5.2) .03
Hematocrita,b <30% 2.9 (1.6 to 5.2) .001
Neutrophilsa,b ≥3000 cells/mm3 2.3 (1.2 to 4.4) .02
Lymphocytesa,b <2000 cells/mm3 2.1 (1.1 to 4.1) .03
Abbreviations: aHR, adjusted hazard ratio; ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; HR, hazard ratio; HIV, human immunodeficiency virus; ref, reference; RNA, ribonucleic acid.
aMissing values were imputed using multiple imputation by chained equations with predictive mean matching.
bAdjusted for age.
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The study sites (number of children enrolled at each site) and investiga-
tors who contributed to this study were as follows: Chiangrai Prachanukroh 
(156), R. Hansudewechakul; Nakornping (120), S. Kanjanavanit; Chonburi 
(48), S. Hongsiriwon; Prapokklao (38), C. Ngampiyaskul; Bhumibol 
Adulyadej (30), J. Mekmullica, P. Layangool, and S. Phongjitsiri; Phayao 
Provincial (30), P. Techakunakorn; Samutsakhon (25), P. Thanasiri and S. 
Krikajornkitti; Kalasin (22), S. Srirojana; Lamphun (20), P. Wannarit, R. 
Somsamai, and R. Kosonsasitorn; Nakhonpathom (14), S. Bunjongpak; 
Rayong (14), W. Karnchanamayul; Somdej Prapinklao (14), M. 
Nantarukchaikul, B. Techasaensiri (Debaval), and N. Kamonpakorn; Mae 
Chan (13), S. Piyaworawong and S. Buranabanjasatean; Samutprakarn 
(12), C. Sriwacharakarn and A. Puangsombat; Doi Saket (10), P. 
Sirichithaporn; Nong Khai (10), S. Potchalongsin; Phaholpolpayuhasaena 
(9), P. Attavinijtrakarn; Chiang Dao (7), A. Saipanya; Buddhachinaraj (6), 
W. Ardong and N. Lertpienthum; Mae Sai (6), R. Paramee, S. Nanta, and 
S. Kunkongkapan; Phan (6), S. Jungpichanvanich and S. Theansavettrakul; 
Regional Health Promotion Centre 6, Khon Kaen (6), S. Hanpinitsak; Hat 
Yai (5), B. Warachit and T. Borkird; Queen Sirikit (5), T. Hinjiranandana; 
Banglamung (4), P. Kanjanavikai; Bhuddasothorn (4), R. Kwanchaipanich; 
Chiang Kham (4), V. Wanchaitanawong; Mahasarakam (4), S. Na-Rajsima; 
Sanpatong (4), N. Akarathum; Mae On (3), N. Pattanapornpun; 
Pranangklao (3), P. Lucksanapisitkul and S. Watanayothin; San Sai (3), W. 
Cowatcharagul; Sankhampang (3), N. Pipattanawong; Bamrasnaradura (2), 
S. Sirikwin; Ratchaburi (2), C. Sutthipong; Roi-et (2), P. Ananpatharachai; 
Srinagarind (2), P. Kosalaraksa; Banchang (1), K. Pattarakunpong and N. 
Sangwannakul; Health Promotion Center Region 10 (1), W. Jitphiankha; 
Phayamengrai (1), S. Laopichianpong; Vachira Phuket (1), W. Lawtongkum.
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